Skip to content
Lincoln Pharmaceuticals logo

Lincoln Pharmaceuticals

LINCOLN NSE
₹545.20 down 12.90 (2.31%)
Market Cap
₹1,092 Cr
P/E
11.32

Lincoln Pharmaceuticals (LINCOLN) share price was ₹558.10 at the 28 Oct 2026 close; market capitalisation ₹1,118 Cr; P/E (TTM) 11.59; sector Healthcare. The share price rose 5.8% over the year to 28 Oct 2026 (adjusted for splits and bonuses). In the Jun 2026 quarter, revenue rose 15.1% year on year to ₹177.3 Cr and net profit rose 30.7% year on year to ₹36.2 Cr (compared with Jun 2025). Promoters held 49.78% of Lincoln Pharmaceuticals in Sep 2026, unchanged from Jun 2026. Its Tapetide Score is 55/100 (Good) as of 28 Oct 2026.

Close 28 Oct 2026 ₹558.10 +25.20 +4.73% 1Y

Key Fundamentals

MicrocapPharmaceuticals & BiotechnologyHealthcare
Market Cap
₹1,092 Cr
P/E (TTM)
11.32
EBITDA
₹131 Cr
Return on Equity
11.6%
Return on Capital Employed
14.97%
Debt to Equity
0.01
Book Value
₹378.25
EPS (TTM)
₹48.16
52W High
₹770.00
52W Low
₹440.00

Price-based figures as of 29 Oct 2026, 11:12 IST · EPS basis: Consolidated · TTM

Peer Comparison

Healthcare › Pharmaceuticals

Sun Pharma
₹1,766.0035.034,23,723 Cr5.070.91%13.79%17.94%61,848 Cr12,117 Cr
Divis Laboratories
₹9,637.5087.472,55,845 Cr15.260.32%15.32%18.96%11,682 Cr2,925 Cr
Torrent Pharmaceuticals
₹4,598.4072.191,74,908 Cr9.520.82%12.16%9.06%17,058 Cr2,156 Cr
Laurus Labs
₹2,184.50107.931,18,031 Cr22.270.09%16.38%19.67%7,323 Cr1,090 Cr
Zydus Life Science
₹1,180.5026.271,17,755 Cr4.340.09%16.99%19.24%28,515 Cr4,593 Cr
Dr Reddys Laboratories
₹1,341.2034.741,11,947 Cr2.880.61%10.87%13.94%34,247 Cr3,184 Cr
Cipla
₹1,370.1032.821,10,685 Cr3.130.96%11.21%14.88%28,589 Cr3,356 Cr
Lincoln Pharmaceuticals (this company)
₹545.2011.321,092 Cr1.440.33%11.60%14.97%737 Cr97 Cr
Median 8 companies₹1,568.0534.891,17,893 Cr4.710.47%12.98%16.46%22,787 Cr3,055 Cr

Comparable companies in the same industry. Market cap, P/E and P/B use the live price; other metrics are as reported in filings. A dash means the figure is not published for that company.

Tapetide Score

Data-driven rating, 0–100, as of . How it works →

55 Good
Overall score

Data confidence 100/100

Category scores

Quality Good 63
Returns, margins, earnings quality 22% weight
Valuation Strong 86
Cheap vs sector & own history 24% weight
Growth Poor 36
Sales & profit trajectory 9% weight
Financial Health Strong 80
Solvency, leverage, coverage 9% weight
Momentum Poor 26
Trend strength, vol-adjusted 12% weight
Ownership Poor 34
FII/DII/promoter flows 24% weight

The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.

Key Insights

Strengths

1
  • Company is almost debt free.

Weaknesses

4
  • The company has delivered a poor sales growth of 9.61% over past five years.
  • Company has a low return on equity of 13.6% over last 3 years.
  • Earnings include an other income of Rs.42.4 Cr.
  • Dividend payout has been low at 4.11% of profits over last 3 years

Technical Indicators

Oscillators

Neutral

Bearish
2
Neutral
5
Bullish
2

Overall

Bearish

Bearish
8
Neutral
5
Bullish
6

Moving Averages

Bearish

Bearish
6
Neutral
0
Bullish
4

Growth Rate

Revenue Growth
9.11% lower than 3Y

change over 1 year

Net Income Growth
6.8% higher than 3Y

change over 1 year

Cash Flow Change
14.34%

change over 1 year

EBITDA Margin Change
-3.07%

change over 1 year Operating margin 15% · Jun 2026

Quarterly Results

Particulars Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales
136
156
146
142
147
161
147
168
154
163
166
187
177
Expenses
115
125
117
124
125
133
123
141
130
138
143
162
150
Operating Profit
21
31
30
18
23
28
24
27
24
25
24
25
27
OPM %
15%
20%
20%
13%
15%
18%
16%
16%
15%
16%
14%
13%
15%
Other Income
8
9
11
7
10
10
9
-7
15
7
15
-4
24
Interest
0
0
0
0
0
0
1
0
0
0
0
0
0
Depreciation
3
3
3
3
3
3
3
3
3
4
4
4
4
PBT
25
37
38
22
29
35
29
16
35
29
35
17
48
Tax %
25%
25%
26%
16%
20%
24%
28%
29%
22%
31%
18%
30%
24%
Net Profit
19
28
28
19
24
26
21
12
28
20
29
12
36
EPS (₹)
9.49
13.8
14
9.29
11.82
13.15
10.37
5.78
13.82
9.98
14.28
5.81
18.09
Figures in ₹ Crores

Profit & Loss

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales
266
400
360
361
366
386
424
472
510
581
623
671
694
Expenses
240
359
313
308
299
321
337
376
421
480
522
573
593
Operating Profit
26
41
47
53
68
66
87
96
90
100
102
98
101
OPM %
10%
10%
13%
15%
18%
17%
21%
20%
18%
17%
16%
15%
15%
Other Income
7
7
2
5
5
11
5
10
22
34
22
33
42
Interest
8
10
7
5
4
2
2
1
2
1
2
1
1
Depreciation
5
5
6
6
7
7
8
8
9
11
13
14
15
PBT
20
33
37
46
62
67
84
96
100
122
109
116
128
Tax %
24%
28%
25%
25%
22%
23%
26%
28%
27%
24%
25%
24%
—
Net Profit
15
24
28
35
49
51
62
69
73
93
82
88
96
EPS (₹)
9.2
14.52
14.06
17.31
24.36
25.72
31.12
34.63
36.4
46.58
41.11
43.88
48.16
Div. Payout %
11%
7%
9%
9%
6%
6%
5%
4%
4%
4%
4%
4%
—
Figures in ₹ Crores

Balance Sheet

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
16
16
20
20
20
20
20
20
20
20
20
20
Reserves
95
124
172
204
249
293
346
413
482
573
652
738
Borrowings
76
78
64
61
34
5
1
2
2
1
0
4
Other Liabilities
70
56
48
62
63
71
85
99
83
106
125
128
Total Liabilities
258
275
305
347
366
389
452
534
587
700
797
890
Fixed Assets
66
98
103
117
121
123
111
132
151
179
182
191
CWIP
3
3
7
0
2
0
2
16
7
3
4
5
Investments
0
0
10
11
18
34
81
97
91
139
174
209
Other Assets
190
174
186
219
225
232
259
290
339
379
437
486
Total Assets
258
275
305
347
366
389
452
534
587
700
797
890
Figures in ₹ Crores

Cash Flow

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating
25
45
25
27
53
75
69
76
39
63
93
106
Investing
7
-42
-25
-12
-18
-31
-64
-78
-37
-57
-79
-98
Financing
-32
-3
0
-11
-36
-38
-6
-3
-4
-5
-6
0
Net Cash Flow
-1
0
0
3
-1
7
-1
-4
-2
1
8
8
Free Cash Flow
21
11
7
17
38
68
61
31
26
24
74
82
CFO/OP
109
126
74
68
104
137
102
104
77
89
117
135
Figures in ₹ Crores

Ratios

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days
163
73
92
111
122
96
98
90
98
102
97
88
Inventory Days
44
36
63
86
75
95
86
121
106
101
99
94
Days Payable
92
40
54
82
92
102
105
120
77
95
106
100
Cash Conversion Cycle
116
70
100
115
106
88
78
91
126
108
90
82
Working Capital Days
76
31
69
89
113
126
119
113
121
121
116
126
ROCE %
15%
21%
19%
19%
23%
22%
25%
24%
22%
22%
17%
16%

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

Log in to view Lincoln Pharmaceuticals insights

67 extracted metrics + investor summaries across FY11–FY27.

Shareholding Pattern

DIIs0.02%Promot.49.78%FIIs4.55%Others9.17%Public36.48%As ofSep 2026

Documents

Frequently Asked Questions about Lincoln Pharmaceuticals

What does Lincoln Pharmaceuticals Ltd do?
Incorporated in 1979, Lincoln Pharmaceuticals Ltd is in the business of manufacturing and trading of pharmaceutical products [1]
Where is Lincoln Pharmaceuticals Ltd (LINCOLN) listed?
Lincoln Pharmaceuticals Ltd trades as LINCOLN on the NSE and under code 531633 on the BSE.
Which sector does Lincoln Pharmaceuticals Ltd belong to?
Lincoln Pharmaceuticals Ltd is classified under the Healthcare sector, in the Pharmaceuticals industry.
What is the market capitalisation of Lincoln Pharmaceuticals Ltd?
Lincoln Pharmaceuticals Ltd has a market capitalisation of ₹1,092 Cr as of 29 Oct 2026, which places it in the Small Cap band.
What is the PE ratio of Lincoln Pharmaceuticals Ltd?
Lincoln Pharmaceuticals Ltd trades at a PE ratio of 11.32 as of 29 Oct 2026, on earnings per share of ₹48.16, against a book value of ₹378.25 per share.
What is the 52-week high and low of Lincoln Pharmaceuticals Ltd?
Over the last 52 weeks Lincoln Pharmaceuticals Ltd has traded between ₹440 and ₹770 as of 29 Oct 2026.
Does Lincoln Pharmaceuticals Ltd pay dividends?
Lincoln Pharmaceuticals Ltd has a dividend yield of 0.32%.
What is the Return on Equity (ROE) of Lincoln Pharmaceuticals Ltd?
Lincoln Pharmaceuticals Ltd reported a return on equity of 11.60%. Its debt-to-equity ratio is 0.01.

Company Information

Incorporated in 1979, Lincoln Pharmaceuticals Ltd is in the business of manufacturing and trading of pharmaceutical products [1]

Website lincolnpharma.com
CEO Mr. Mahendrabhai Gulabdas Patel B.A, LLB
Employees 1,853
Listed 2004-10-21
Face Value ₹ 10
Shares Outstanding 2,00,29,728

For AI agents and developers

Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/LINCOLN.md for Lincoln Pharmaceuticals Ltd: company profile, latest price, key fundamentals, the Tapetide Score, growth rates, quarterly and annual financial statements, shareholding pattern, technical indicators, analyst ratings and exchange filings.

Append .md to any Tapetide URL for the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live, structured queries instead of documents, use our Indian stock market MCP server.

Explore More

More Pharma stocks → FII DII DataStock ScreenerNifty 50 HeatmapF&O Ban ListFII and DII flows, month by monthHow Tapetide Scores changed, month by monthStocks mutual funds are buying, month by month